TY - JOUR
T1 - Protein farnesyltransferase
T2 - Flexible docking studies on inhibitors using computational modeling
AU - Guida, Wayne C.
AU - Hamilton, Andrew D.
AU - Crotty, Justin W.
AU - Sebti, Saïd M.
N1 - Funding Information:
We thank the National Institutes of Health (CA67771) for financial support of this work. We also thank Dr. Corey Strickland of Schering Plough for supplying us with the coordinates of the X-ray structures of FTI-276 and FTI-2148. We thank Mr. Matt Maderios of Eckerd College for assistance with the docking studies performed on DPI-1.
PY - 2005/12
Y1 - 2005/12
N2 - Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER*force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.
AB - Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER*force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.
KW - Docking
KW - Drug design
KW - Flexible docking
KW - Molecular modeling
KW - Protein farnesyltransferase
UR - http://www.scopus.com/inward/record.url?scp=33744947824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33744947824&partnerID=8YFLogxK
U2 - 10.1007/s10822-005-9030-2
DO - 10.1007/s10822-005-9030-2
M3 - Article
C2 - 16607571
AN - SCOPUS:33744947824
SN - 0920-654X
VL - 19
SP - 871
EP - 885
JO - Journal of Computer-Aided Molecular Design
JF - Journal of Computer-Aided Molecular Design
IS - 12
ER -